 Halozyme Therapeutics Inc NASDAQ: HALO will acquire Antares Pharma Inc NASDAQ: ATRS for 5.60 per share, valuing Antares at approximately 960 million. The transaction is expected to be accretive to Halozymes 2022 revenue and adjusted earnings and accelerate top-. 